Picture of the Favourable Immune Profile Induced by Anti-SARS-CoV-2 Vaccination
Authors:
- Paola LanutiPLPaola Lanuti
- Claudia RossiClaudia Rossi
- Ilaria CicaliniIlaria Cicalini
- Laura PierdomenicoLPLaura Pierdomenico
- Verena DamianiVDVerena Damiani
- Daniela SemeraroDSDaniela Semeraro
- Sara VerrocchioSVSara Verrocchio
- Piero Del BoccioPiero Del Boccio
- Adelia EvangelistaAEAdelia Evangelista
- Annalina SarraASAnnalina Sarra
- Mirco ZucchelliMZMirco Zucchelli
- Giuseppina BolognaGBGiuseppina Bologna
Open Access
- 18 August 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (8) , 1035
Abstract
COVID-19 pandemic has hit people’s health, economy, and society worldwide. Great confidence in returning to normality has been placed in the vaccination campaign. The knowledge of individual immune profiles and the time required to achieve immunological protection is crucial to choose the best vaccination strategy. We compared anti-S1 antibody levels produced over time by BNT162b2 and AZD1222 vaccines and evaluated the induction of antigen-specific T-cells. A total of 2569 anti-SARS-CoV-2 IgG determination on dried blood spot samples were carried out, firstly in a cohort of 1181 individuals at random time-points, and subsequently, in an independent cohort of 88 vaccinated subjects, up to the seventeenth week from the first dose administration. Spike-specific T-cells were analysed in seronegative subjects between the two doses. AZD1222 induced lower anti-S1 IgG levels as compared to BNT162b2. Moreover, 40% of AZD1222 vaccinated subjects and 3% of BNT162b2 individuals resulted in seronegative during all the time-points, between the two doses. All these subjects developed antigen-specific T cells, already after the first dose. These results suggest that this test represents an excellent tool for a wide sero-surveillance. Both vaccines induce a favourable immune profile guaranteeing efficacy against severe adverse effects of SARS-CoV-2 infection, already after the first dose administration.Keywords
This publication has 12 references indexed in Scilit:
- Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 InfectionViruses, 2021
- Oxford–AstraZeneca COVID-19 vaccine efficacyThe Lancet, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialNature Medicine, 2020
- Validation of Dried Blood Spot Sample Modifications to Two Commercially Available Covid-19 Igg Antibody ImmunoassaysBioanalysis, 2020
- Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 casesbioRxiv, 2020
- Dried Blood Spot as an Alternative to Plasma/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized to Facilitate COVID-19 Surveillance Among SchoolchildrenThe Pediatric Infectious Disease Journal, 2020
- An Effective COVID-19 Vaccine Needs to Engage T CellsFrontiers in Immunology, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020